Global Blood Transfusion Diagnostics Market - Forecasts from 2018 to 2023
The global blood transfusion diagnostics market is expected to grow at a CAGR of 5.48% during the forecast period of 2017-2023. Blood transfusion diagnostics include the instruments that are used to screen and conduct tests before transfusion of blood and blood products from donor to recipient. The instruments include analyzers, centrifuges, kits and reagents for diagnosis of the disease etc. The rise in the market may be attributed to the rising number of infectious diseases coupled with the rise in demand for blood and blood components transfusions owing to large patient population base suffering from diseases such as aplastic anemia, thalassemia, and leukemia. Rising incidences of the chronic diseases requiring blood transfusions is further expected to drive demand for blood transfusion diagnostics. As per report by WHO, haemoglobin disorders (sickle-cell disorders and thalassemia's) were originally endemic in 60% of 229 countries, potentially affecting 75% of births, but are now sufficiently common in 71% of countries among 89% of births. However, lack of skilled professionals for the blood transfusion diagnostics may hamper the growth of the market during the given forecast period.
This research study examines the current market trends related to the demand, supply, and sales, in addition to the recent developments. Major drivers, restraints, and opportunities have been covered to provide an exhaustive picture of the market. The analysis presents in-depth information regarding the development, trends, and industry policies and regulations implemented in each of the geographical region. Further, the overall regulatory framework of the market has been exhaustively covered to offer stakeholders a better understanding of the key factors affecting the overall market environment.
Identification of key industry players in the industry and their revenue contribution to the overall business or relevant segment aligned to the study have been covered as a part of competitive intelligence done through extensive secondary research. Various studies and data published by industry associations, analyst reports, investor presentations, press releases and journals among others have been taken into consideration while conducting the secondary research. Both bottom-up and top down approaches have been utilized to determine the market size of the overall market and key segments. The values obtained are correlated with the primary inputs of the key stakeholders in the global blood transfusion diagnostics market value chain. Last step involves complete market engineering which includes analysing the data from different sources and existing proprietary datasets while using various data triangulation methods for market breakdown and forecasting.
Market intelligence is presented in the form of analysis, charts, and graphics to help the clients in gaining faster and efficient understanding of the global smart syringes market.
Major industry players profiled as part of the report are F. Hoffmann-La Roche Ltd., Diagast and Abbott among others.
Segmentation
This research study examines the current market trends related to the demand, supply, and sales, in addition to the recent developments. Major drivers, restraints, and opportunities have been covered to provide an exhaustive picture of the market. The analysis presents in-depth information regarding the development, trends, and industry policies and regulations implemented in each of the geographical region. Further, the overall regulatory framework of the market has been exhaustively covered to offer stakeholders a better understanding of the key factors affecting the overall market environment.
Identification of key industry players in the industry and their revenue contribution to the overall business or relevant segment aligned to the study have been covered as a part of competitive intelligence done through extensive secondary research. Various studies and data published by industry associations, analyst reports, investor presentations, press releases and journals among others have been taken into consideration while conducting the secondary research. Both bottom-up and top down approaches have been utilized to determine the market size of the overall market and key segments. The values obtained are correlated with the primary inputs of the key stakeholders in the global blood transfusion diagnostics market value chain. Last step involves complete market engineering which includes analysing the data from different sources and existing proprietary datasets while using various data triangulation methods for market breakdown and forecasting.
Market intelligence is presented in the form of analysis, charts, and graphics to help the clients in gaining faster and efficient understanding of the global smart syringes market.
Major industry players profiled as part of the report are F. Hoffmann-La Roche Ltd., Diagast and Abbott among others.
Segmentation
- By Product Type
- Instruments
- Kits & Reagents
- By Technology
- ELISA
- Western Blotting
- Nucleic Acid Amplification
- Others
- By End-User
- Hospitals and Clinics
- Diagnostic Labs
- Blood Banks
- By Geography
- North America
- United States
- Canada
- Others
- South America
- Brazil
- Argentina
- Others
- Europe
- United Kingdom
- Germany
- France
- Others
- Middle East and Africa
- Saudi Arabia
- UAE
- Israel
- Others
- Asia Pacific
- China
- India
- Australia
- South Korea
- Others
1. INTRODUCTION
1.1. Market Definition
1.2. Scope of the Study
1.3. Currency
1.4. Assumptions
1.5. Base, and Forecast Years Timeline
2. RESEARCH METHODOLOGY
2.1. Research Design
2.2. Secondary Sources
2.3. Validation
3. KEY FINDINGS OF THE STUDY
4. MARKET DYNAMICS
4.1. Drivers
4.2. Restraints
4.3. Opportunities and Market Trends
4.4. Market Segmentation
4.5. Porter’s Five Forces Analysis
4.5.1. Bargaining Power of Suppliers
4.5.2. Bargaining Power of Buyers
4.5.3. Threat of New Entrants
4.5.4. Threat of Substitutes
4.5.5. Competitive Rivalry in the Industry
4.6. Industry Value Chain Analysis
4.7. Industry Regulations
4.8. Scenario Analysis
5. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET FORECAST BY TYPE
5.1. Instruments
5.2. Kits & Reagents
6. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET FORECAST BY TECHNOLOGY
6.1. ELISA
6.2. Western Blotting
6.3. Nucleic Acid Amplification
6.4. Others
7. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET FORECAST BY END USERS
7.1. Hospitals and Clinics
7.2. Diagnostic Labs
7.3. Blood Banks
8. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET FORECAST BY GEOGRAPHY
8.1. North America
8.1.1. The U.S
8.1.2. Canada
8.1.3. Mexico
8.1.4. Others
8.2. South America
8.2.1. Brazil
8.2.2. Argentina
8.2.3. Others
8.3. Europe
8.3.1. U.K.
8.3.2. France
8.3.3. Germany
8.3.4. Italy
8.3.5. Others
8.4. Middle East and Africa
8.4.1. Saudi Arabia
8.4.2. UAE
8.4.3. Israel
8.4.4. Others
8.5. Asia Pacific
8.5.1. China
8.5.2. India
8.5.3. Australia
8.5.4. South Korea
8.5.5. Others
9. COMPETITIVE INTELLIGENCE
9.1. Market Share Analysis
9.2. Strategies of Key Players
9.3. Recent Investments and Deals
10. COMPANY PROFILES
10.1. Quotient, Ltd.
10.1.1. Overview
10.1.2. Financials
10.1.3. Product and Services
10.1.4. Recent Developments
10.2. BAG HealthCare
10.2.1. Overview
10.2.2. Financials
10.2.3. Product and Services
10.2.4. Recent Developments
10.3. Abbott
10.3.1. Overview
10.3.2. Financials
10.3.3. Product and Services
10.3.4. Recent Developments
10.4. Immucor
10.4.1. Overview
10.4.2. Financials
10.4.3. Product and Services
10.4.4. Recent Developments
10.5. Diasorin SPA
10.5.1. Overview
10.5.2. Financials
10.5.3. Product and Services
10.5.4. Recent Developments
10.6. Bio-Rad Laboratories, Inc
10.6.1. Overview
10.6.2. Financials
10.6.3. Product and Services
10.6.4. Recent Developments
10.7. GRIFOLS AUSTRALIA Pty Ltd
10.7.1. Overview
10.7.2. Financials
10.7.3. Product and Services
10.7.4. Recent Developments
10.8. F. Hoffmann-La Roche Ltd.
10.8.1. Overview
10.8.2. Financials
10.8.3. Product and Services
10.8.4. Recent Developments
10.9. Beckman Coulter, Inc.
10.9.1. Overview
10.9.2. Financials
10.9.3. Product and Services
10.9.4. Recent Developments
10.10. DIAGAST
10.10.1. Overview
10.10.2. Financials
10.10.3. Product and Services
10.10.4. Recent Developments
1.1. Market Definition
1.2. Scope of the Study
1.3. Currency
1.4. Assumptions
1.5. Base, and Forecast Years Timeline
2. RESEARCH METHODOLOGY
2.1. Research Design
2.2. Secondary Sources
2.3. Validation
3. KEY FINDINGS OF THE STUDY
4. MARKET DYNAMICS
4.1. Drivers
4.2. Restraints
4.3. Opportunities and Market Trends
4.4. Market Segmentation
4.5. Porter’s Five Forces Analysis
4.5.1. Bargaining Power of Suppliers
4.5.2. Bargaining Power of Buyers
4.5.3. Threat of New Entrants
4.5.4. Threat of Substitutes
4.5.5. Competitive Rivalry in the Industry
4.6. Industry Value Chain Analysis
4.7. Industry Regulations
4.8. Scenario Analysis
5. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET FORECAST BY TYPE
5.1. Instruments
5.2. Kits & Reagents
6. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET FORECAST BY TECHNOLOGY
6.1. ELISA
6.2. Western Blotting
6.3. Nucleic Acid Amplification
6.4. Others
7. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET FORECAST BY END USERS
7.1. Hospitals and Clinics
7.2. Diagnostic Labs
7.3. Blood Banks
8. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET FORECAST BY GEOGRAPHY
8.1. North America
8.1.1. The U.S
8.1.2. Canada
8.1.3. Mexico
8.1.4. Others
8.2. South America
8.2.1. Brazil
8.2.2. Argentina
8.2.3. Others
8.3. Europe
8.3.1. U.K.
8.3.2. France
8.3.3. Germany
8.3.4. Italy
8.3.5. Others
8.4. Middle East and Africa
8.4.1. Saudi Arabia
8.4.2. UAE
8.4.3. Israel
8.4.4. Others
8.5. Asia Pacific
8.5.1. China
8.5.2. India
8.5.3. Australia
8.5.4. South Korea
8.5.5. Others
9. COMPETITIVE INTELLIGENCE
9.1. Market Share Analysis
9.2. Strategies of Key Players
9.3. Recent Investments and Deals
10. COMPANY PROFILES
10.1. Quotient, Ltd.
10.1.1. Overview
10.1.2. Financials
10.1.3. Product and Services
10.1.4. Recent Developments
10.2. BAG HealthCare
10.2.1. Overview
10.2.2. Financials
10.2.3. Product and Services
10.2.4. Recent Developments
10.3. Abbott
10.3.1. Overview
10.3.2. Financials
10.3.3. Product and Services
10.3.4. Recent Developments
10.4. Immucor
10.4.1. Overview
10.4.2. Financials
10.4.3. Product and Services
10.4.4. Recent Developments
10.5. Diasorin SPA
10.5.1. Overview
10.5.2. Financials
10.5.3. Product and Services
10.5.4. Recent Developments
10.6. Bio-Rad Laboratories, Inc
10.6.1. Overview
10.6.2. Financials
10.6.3. Product and Services
10.6.4. Recent Developments
10.7. GRIFOLS AUSTRALIA Pty Ltd
10.7.1. Overview
10.7.2. Financials
10.7.3. Product and Services
10.7.4. Recent Developments
10.8. F. Hoffmann-La Roche Ltd.
10.8.1. Overview
10.8.2. Financials
10.8.3. Product and Services
10.8.4. Recent Developments
10.9. Beckman Coulter, Inc.
10.9.1. Overview
10.9.2. Financials
10.9.3. Product and Services
10.9.4. Recent Developments
10.10. DIAGAST
10.10.1. Overview
10.10.2. Financials
10.10.3. Product and Services
10.10.4. Recent Developments
